Dyne therapeutics ipo
WebSep 17, 2024 · Dyne Therapeutics’ IPO and CureDuchenne’s timely funding is an exemplary model of the CureDuchenne venture philanthropy approach. The CureDuchenne Ventures investment made at a critical time in March 2024 helped Dyne de-risk the science and establish proof-of-concept. They were able to keep working, … WebSep 17, 2024 · Dyne Therapeutics raised $233 million in an initial public offering of 12.3 million shares of its common stock at $19.00 per share. ... 40 percent of the money raised by drug developers in IPOs in 2024. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in the rare genetic wasting diseases myotonic ...
Dyne therapeutics ipo
Did you know?
WebSep 17, 2024 · Amid a parade of upsized biotech IPOs this year, Dyne Therapeutics in Waltham made its debut with a $233 million fundraise — more than double what it said it was hoping to bring in when it first ... WebPost IPO equity ... Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically …
WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically …
WebSep 1, 2024 · Dyne Therapeutics (DYN) aims to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The … WebMar 14, 2024 · 天眼查为您提供Dyne Therapeutics Inc.的企业信息查询服务,查询Dyne Therapeutics Inc.工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营风险、公司发展状况、公司财务状况、公司股东法人高管、商标、融资、专利、法律诉讼等Dyne Therapeutics Inc.企业信用信息,想了解Dyne Therapeutics Inc.怎么样,就 ...
Web26 rows · Dyne Therapeutics, Inc. Financial Information: Market Cap: $707.8mil: Revenues: $0 mil (last 12 ...
WebSep 16, 2024 · WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing … shanghai bay portsmouthWebSep 21, 2024 · Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral ... shanghai battlefield 4WebApr 11, 2024 · Dyne Therapeutics has a 52-week low of $4.30 and a 52-week high of $15.63. Dyne Therapeutics ( NASDAQ:DYN - Get Rating ) last issued its quarterly earnings data on Thursday, March 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10. shanghai bay restaurant southamptonWebSep 12, 2024 · Dyn Therapeutics (DYN) has filed to raise $175 million from the sale of its common stock in an IPO, according to an amended registration statement.. The company is a preclinical stage developer of ... shanghai bay southampton englandWebOct 13, 2024 · Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day. October 13, 2024 07:45 ET Source: Dyne Therapeutics, Inc ... shanghai bay southampton menuWebApr 12, 2024 · Since the IPO on September 17, 2024, Dyne Therapeutics, Inc.'s market cap has decreased from $790.90M to $480.56M, a decrease of -39.24%. That is a compound annual growth rate of -17.66%. shanghai bbc journalistWebMar 14, 2024 · 天眼查为您提供Dyne Therapeutics Inc.的企业信息查询服务,查询Dyne Therapeutics Inc.工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营风险、 … shanghai bdgene co. ltd